Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company that is developing innovative precision medicine for debilitating musculoskeletal diseases. The Company is leveraging its knowledge and expertise in muscle biology, biophysics and small molecules to create a pipeline of candidates that address large unmet...
CytoKinetics, Inc. (NASDAQ: CYTK), a late-stage biopharmaceutical company, is developing therapeutics for the treatment of cardiovascular and neuromuscular diseases that are characterized by impaired muscle function such as amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA) heart failure and hypertrophic cardiomyopathies (HCM). The Company announced preclinical...
Biotech Companies continue to show resurgence even in these challenging times, with more and more companies persevering with bringing their clinical candidates to fruition. While Vaccine development and therapeutics to combat the COVID-19 pandemic are at the forefront of development activities in the biotech sector,...
MannKind Corporation (NASDAQ: MNKD) is a biopharmaceutical company that is leveraging its unique Technosphere Technology, to develop and commercialize inhaled therapeutics, for the treatment of endocrine and orphan lung diseases. The Company’s work is based on the foresight of the visionary inventor and Alfred E....
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company, is developing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, an approach that has the potential to address the unmet needs in cardiovascular, metabolic and fatty liver diseases. The Company’s research is...
There is a lot of buzz around Acer Therapeutics (NASDAQ: ACER) resulting in the stock zooming skywards. The sudden interest in the company is based on rumors that the Company is likely to be acquired by Relief Therapeutics (OTCQB: RLFTF), a biopharmaceutical company whose lead...
Albireo Pharma, Inc. (NASDAQ: ALBO) a clinical-stage company targeting rare liver diseases, announced the acceptance of its New Drug Application (NDA) for odevixibat, a once-daily, non-systemic IBAT, intended for the treatment of pruritus in patients with progressive familial intrahepatic cholestasis (PFIC). The candidate is also...
Equillium Bio (NASDAQ: EQ), a clinical–stage biopharmaceutical Company focused on bringing innovation in form of immune-modifying therapies to treat immuno-inflammatory diseases, announced the receipt of a Study May Proceed letter from the U.S Food and Drug Administration (FDA), to evaluate the company’s lead asset itolizumab,...
Galera Therapeutics (NASDAQ: GRTX), a clinical–stage Biopharmaceutical Company aiming to redefine radiotherapy in cancer, announced positive interim results from a phase 1/2 trial of GC4419 or avasopasem manganese. An investigational, highly selective small molecule superoxide dismutase mimetic, GC4419 has the potential to convert superoxide to...
Zosano Pharma (NASDAQ: ZSAN), a clinical-stage biopharmaceutical Company, announced the acceptance of the Company’s New Drug Application for Qtrypta™, a proprietary formulation of Zolmitriptan by the U.S Food and Drug Administration (FDA) for filing and substantive review. The FDA has set a The Prescription Drug...
